Related Experiment Videos
[Pulmonary fibrosis due to bleomycin]
Abstract:
Being little myelotoxic, Bleomycin (BLM) is more and more used in association with other anti-neoplastic drugs; its pulmonary toxicity is not to be overlooked and here is a recall of the risks of pulmonary fibrosis during treatment by BLM. This review is based on a personal experience of 45 cases, of which 6 were cases of respiratory insufficiency. It derived also from a study of the literature which expressed the frequency of respiratory accidents in figures varying from 2 to 94% according to the criteria of tolerance used by the authors. BLM toxicity for the pulmonary tract being important some precautions should be taken in its use: specially supervising aged patients or those with a pastpathological respiratory story; it should particularly concern the functional side, using CO ductance to trace the first signs of toxicity A total dose of 450 mg should not be exceeded.
Insights
Bleomycin (BLM) is increasingly used with other cancer drugs due to low myelotoxicity. However, pulmonary fibrosis risk necessitates careful patient monitoring and dose limitation to prevent respiratory complications.
Area of Science:
- Oncology
- Pulmonology
- Pharmacology
Background:
- Bleomycin (BLM) is a widely used anti-neoplastic agent, often in combination therapies.
- Its reduced myelotoxicity makes it a preferred choice, but pulmonary toxicity remains a significant concern.
Observation:
- This review synthesizes data from 45 patient cases, including 6 with respiratory insufficiency.
- Literature review indicates respiratory complications ranging from 2% to 94% depending on assessment criteria.
Findings:
- Bleomycin-induced pulmonary fibrosis is a serious risk associated with BLM treatment.
- Early detection of pulmonary toxicity is crucial, with carbon monoxide (CO) diffusion capacity recommended for monitoring.
Implications:
- Close supervision of elderly patients and those with pre-existing respiratory conditions is essential.
- A maximum cumulative dose of 450 mg of Bleomycin should not be exceeded to mitigate pulmonary risks.